Carol Nuechterlein

Carol Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.

She currently serves as a director at AveXis, Inc. and Lysosomal Therapeutics, Inc. and Second Genome and a board observer on Allakos and 23andMe. Carole also led the investments on Alios, Ambit, Ambrx, Conatus, Envoy, Nereus & Pharmasset and served as a board observer for all of these except Pharmasset.

She has a BA from Valparaiso University and a JD from University of Michigan.